Jazz Pharmaceuticals plc (NASDAQ:JAZZ) biopharmaceutical will be discussing 2Q20 financial results with the investment community.on 4th August 2020 at 4:30 PM eastern time.
Those interested in listening to the conference call live via the Internet can visit www.jazzpharma.com
Earnings Expectation
Jazz Pharmaceuticals plc is set to announce second quarter earning results on Tuesday 4th August 2020, after market close.
Analysts surveyed by Thomson Reuters are predicting, JAZZ to report 2Q20 income of $ 3.11 per share. For the full year, analysts anticipate top line of $ 2201.55 million, while looking forward to income of $ 11.73 per share bottom line.
The Company Outlook
Full Year 2020 topline are forecasted in a range of$ 2,120.00 million ~ $ 2,260.00 million, where as bottomline are predicted in a range of $ 11.25 ~ $ 12.50 per share
Click Here For More Historical Outlooks Of Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in adult and pediatric patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia.
